Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Kowa, MEDRx Announce Agreement for Etodolac Patch
April 4, 2011
- Recruiting Is the Lifeblood of Any Company
April 4, 2011
- Meiji Seika Licenses Ziprasidone from RaQualia
April 4, 2011
- Vaccination with Prevnar, ActHIB to Resume April 1
April 4, 2011
- R-Tech Ueno Licenses Unoprostone to Sucampo
April 4, 2011
- Pharma Design Licenses Part of Its Rights to Cancer Transcription Factors to Yakult
April 4, 2011
- BI Ties Up with MorphoSys to Manufacture Biopharmaceuticals
April 4, 2011
- Oncology Strategies of Top-four Japanese Pharmaceutical Companies
April 4, 2011
- Reminyl for AD: Takeda, Janssen
April 4, 2011
- Oncology Strategies of Top-four Japanese Pharmaceutical Companies
March 28, 2011
- Nichi-Iko Acquires Additional Shares from Aprogen
March 28, 2011
- JSMI Presents List of OTC Drugs Available Free of Charge
March 28, 2011
- Takeda Suspends PII Trial for Anti-obesity Drug in US
March 28, 2011
- 14 Hokoku-hinmoku Included in NHI Price List
March 28, 2011
- MTPC Ties Up with Kyoto Univ. to Develop Drugs for Kidney Disease
March 28, 2011
- Korosho Calls For Reasonable Ordering Practices from Med. Institutions, Pharmacies
March 28, 2011
- JMA to Dispatch JMATs to Disaster Area
March 28, 2011
- Both AZ, Plaintiffs Appeal to High Court
March 28, 2011
- NIRS Dispatches 3 Teams to Fukushima
March 28, 2011
- JAMS to Promote Industry-Academia Alliances by Increasing COI Transparency
March 28, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…